Skip to Content

Ceftaroline Dosage

Medically reviewed on July 5, 2016.

Applies to the following strengths: 400 mg; 600 mg

Usual Adult Dose for Pneumonia

600 mg via IV infusion every 12 hours

Duration of therapy:
-Acute bacterial skin and skin structure infections (ABSSSI): 5 to 14 days
-Community-acquired bacterial pneumonia (CABP): 5 to 7 days

Uses:
-For the treatment of ABSSSI due to susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, S agalactiae, Escherichia coli, Klebsiella pneumoniae, and K oxytoca
-For the treatment of CABP due to susceptible isolates of S pneumoniae (including cases with concurrent bacteremia), S aureus (methicillin-susceptible isolates only), Haemophilus influenzae, K pneumoniae, K oxytoca, and E coli

Usual Adult Dose for Skin and Structure Infection

600 mg via IV infusion every 12 hours

Duration of therapy:
-Acute bacterial skin and skin structure infections (ABSSSI): 5 to 14 days
-Community-acquired bacterial pneumonia (CABP): 5 to 7 days

Uses:
-For the treatment of ABSSSI due to susceptible isolates of Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, S agalactiae, Escherichia coli, Klebsiella pneumoniae, and K oxytoca
-For the treatment of CABP due to susceptible isolates of S pneumoniae (including cases with concurrent bacteremia), S aureus (methicillin-susceptible isolates only), Haemophilus influenzae, K pneumoniae, K oxytoca, and E coli

Usual Pediatric Dose for Pneumonia

2 months to less than 2 years: 8 mg/kg via IV infusion every 8 hours
2 years to less than 18 years (up to 33 kg): 12 mg/kg via IV infusion every 8 hours
2 years to less than 18 years (greater than 33 kg): 400 mg via IV infusion every 8 hours or 600 mg via IV infusion every 12 hours

Duration of therapy: 5 to 14 days

Uses:
-For the treatment of ABSSSI due to susceptible isolates of S aureus (including methicillin-susceptible and -resistant isolates), S pyogenes, S agalactiae, E coli, K pneumoniae, and K oxytoca
-For the treatment of CABP due to susceptible isolates of S pneumoniae (including cases with concurrent bacteremia), S aureus (methicillin-susceptible isolates only), H influenzae, K pneumoniae, K oxytoca, and E coli

Usual Pediatric Dose for Skin and Structure Infection

2 months to less than 2 years: 8 mg/kg via IV infusion every 8 hours
2 years to less than 18 years (up to 33 kg): 12 mg/kg via IV infusion every 8 hours
2 years to less than 18 years (greater than 33 kg): 400 mg via IV infusion every 8 hours or 600 mg via IV infusion every 12 hours

Duration of therapy: 5 to 14 days

Uses:
-For the treatment of ABSSSI due to susceptible isolates of S aureus (including methicillin-susceptible and -resistant isolates), S pyogenes, S agalactiae, E coli, K pneumoniae, and K oxytoca
-For the treatment of CABP due to susceptible isolates of S pneumoniae (including cases with concurrent bacteremia), S aureus (methicillin-susceptible isolates only), H influenzae, K pneumoniae, K oxytoca, and E coli

Renal Dose Adjustments

Adults:
-CrCl greater than 50 mL/min: No adjustment recommended.
-CrCl greater than 30 to 50 mL/min: 400 mg via IV infusion every 12 hours
-CrCl 15 to 30 mL/min: 300 mg via IV infusion every 12 hours
-ESRD (CrCl less than 15 mL/min): 200 mg via IV infusion every 12 hours

Pediatrics:
-CrCl greater than 50 mL/min/1.73 m2: No adjustment recommended.
-CrCl less than 50 mL/min/1.73 m2: Data not available

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 2 months.

Consult WARNINGS section for additional precautions.

Dialysis

Adults:
-Hemodialysis: 200 mg IV every 12 hours
-CAPD: Data not available

Comments:
-Because this drug is hemodialyzable, it should be administered after hemodialysis on hemodialysis days.

Pediatrics: Data not available

Other Comments

Administration advice:
-Administer via IV infusion over 5 minutes to 1 hour.
-Therapy duration should be guided by severity and site of infection and by patient's clinical and bacteriological progress.

Storage requirements:
-Unreconstituted vials: Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F).
-Constituted solution in infusion bag or Baxter(R) Mini-Bag Plus(TM): Store for up to 6 hours at room temperature or for up to 24 hours at 2C to 8C (36F to 46F), including infusion time

Reconstitution/preparation techniques:
-The manufacturer product information should be consulted.
-Final volume for infusion into patients should be between 50 to 250 mL.

IV compatibility:
-Compatible: Sterile water for injection; 0.9% sodium chloride injection; 5% dextrose injection; 2.5% dextrose injection; 0.45% sodium chloride injection; lactated ringer's injection
-Compatibility with other drugs not established; should not mix with or physically add to solutions containing other drugs.

General:
-To reduce the development of drug-resistant organisms and maintain effective therapy, this drug should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria.
-Appropriate specimens for microbiological testing recommended before therapy to isolate and identify infecting organisms and to establish susceptibility to this drug.
-Culture and susceptibility information should be considered when selecting/modifying antibacterial therapy or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy.

Patient advice:
-Avoid missing doses and complete the entire course of therapy.
-Contact healthcare provider if severe watery or bloody diarrhea occurs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide